LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Study acronym: LUNAR-2
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 98 → 104 locations
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 14 entries
    • Study description expanded, about 3 words
  2. Study sites: 90 to 98v17
  3. Study sites: 88 to 90v16
  4. Study sites: 84 to 88v15
  5. Study sites: 81 to 84v14
Show 12 earlier versionsHide 12 earlier versions
  1. Study sites: 78 to 81v13
  2. Study sites revised (78)v12
  3. Eligibility criteria expanded, about 9 words
    • Site contacts updated at 9 of 78 sites
    • Study description expanded, about 1 word
    v11
  4. Study sites: 72 to 78v10
  5. Study sites: 59 to 72v9
  6. Study sites: 67 to 59v8
  7. Study sites: 66 to 67v7
  8. Study sites: 64 to 66v6
  9. Study sites: 30 to 64v5
  10. Study sites: 31 to 30v4
  11. Study sites: 3 to 31v3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2024 to Jul 31, 2024
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Trial Details
NCT Number NCT06216301
Lead Sponsor NovoCure GmbH
Conditions
(from sponsor)		 Metastatic Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Enrollment 734 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov